BIOMAT Database Logo BIOMAT Database Logo

Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply. 2021

Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University, New Haven, CT, USA.

UI MeSH Term Description Entries
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001596 Benzylamines Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group. Phenylmethylamine,alpha-Aminotoluene,alpha Aminotoluene
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.

Related Publications

Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Mavacamten for hypertrophic obstructive cardiomyopathy.
January 2021, Lancet (London, England),
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy.
June 2022, The Medical letter on drugs and therapeutics,
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China.
October 2023, JAMA cardiology,
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
January 2023, Cardiovascular & hematological agents in medicinal chemistry,
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
June 2019, Annals of internal medicine,
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
June 2021, Current cardiology reports,
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
October 2023, Journal of clinical medicine,
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Hypertrophic cardiomyopathy - Authors' reply.
April 2013, Lancet (London, England),
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.
February 2024, Mayo Clinic proceedings,
Daniel Jacoby, and Carolyn Y Ho, and Steven J Lester, and Andrew Wang, and Iacopo Olivotto
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients.
May 2023, Trends in pharmacological sciences,
Copied contents to your clipboard!